Dual Antigen Targeting with Talquetamab plus Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma By Ogkologos - January 20, 2025 813 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the RedirecTT-1 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Joins WHO Global Clinical Trials Forum to Strengthen Global Oncology Research Ecosystems EMA Recommends Extension of Therapeutic Indications for Enfortumab Vedotin Selinexor plus Ruxolitinib Reduces Spleen Volume, but Does Not Improve Symptom Responses Over Ruxolitinib in Patients with JAK Inhibitor-Naïve Myelofibrosis MOST POPULAR EMA Recommends Granting a Conditional Marketing Authorisation for Epcoritamab August 17, 2023 Easing Concerns about Giving Research Study Participants Their Genetic Test Results June 1, 2018 Access to Cancer Medicines and Clinical Trials Show Stark Variations Across... September 17, 2020 EMA Recommends Extension of Therapeutic Indications for Polatuzumab Vedotin April 14, 2022 Load more HOT NEWS How My Inherited Cancer Diagnosis Has Made Me a Better Oncologist Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive... Taking on DNA repair to tackle cancer Efficacy of Sunitinib in Patients with Metastatic Phaeochromocytomas and Paragangliomas
